trending Market Intelligence /marketintelligence/en/news-insights/trending/0rxxwemexgel_8ntdj0k2a2 content esgSubNav
In This List

Arch Biopartners raises C$1.3M to advance drug portfolio

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Arch Biopartners raises C$1.3M to advance drug portfolio

Arch Biopartners Inc. said it raised C$1.3 million after selling 2.5 million of its shares at 50 Canadian cents apiece.

The Toronto-based drug developer intends to use a portion of the proceeds to fund a phase 1 inhalation safety trial for AB569, a medicine for treating drug-resistant bacterial infections in the lungs and urinary tract.

The remaining proceeds will be used to develop metablok, a drug candidate for inhibiting acute kidney injury, septic shock and cancer metastasis.